 Eva Nozik
Concepts (380)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Superoxide Dismutase | 22 | 2025 | 346 | 6.310 |
Why?
| | Hypertension, Pulmonary | 25 | 2025 | 1910 | 2.760 |
Why?
| | Acute Lung Injury | 8 | 2023 | 287 | 2.520 |
Why?
| | Hypoxia | 10 | 2025 | 1112 | 2.230 |
Why?
| | Pneumonia, Staphylococcal | 2 | 2025 | 23 | 1.710 |
Why?
| | Lung | 29 | 2025 | 4060 | 1.620 |
Why?
| | Vascular Remodeling | 7 | 2025 | 193 | 1.530 |
Why?
| | Blood Platelets | 4 | 2025 | 408 | 1.480 |
Why?
| | Hyaluronic Acid | 3 | 2025 | 225 | 1.460 |
Why?
| | Mice, Inbred C57BL | 21 | 2025 | 5757 | 1.440 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2024 | 2189 | 1.230 |
Why?
| | Bleomycin | 8 | 2018 | 248 | 1.230 |
Why?
| | Platelet Activation | 4 | 2025 | 93 | 1.160 |
Why?
| | Pulmonary Artery | 13 | 2021 | 1086 | 1.080 |
Why?
| | Pneumonia | 5 | 2022 | 639 | 1.060 |
Why?
| | Hypertrophy, Right Ventricular | 8 | 2022 | 145 | 0.990 |
Why?
| | Mice | 38 | 2025 | 17787 | 0.960 |
Why?
| | Animals | 61 | 2025 | 36940 | 0.930 |
Why?
| | Oxidation-Reduction | 6 | 2023 | 1060 | 0.910 |
Why?
| | Lung Injury | 5 | 2021 | 219 | 0.890 |
Why?
| | Reactive Oxygen Species | 9 | 2025 | 622 | 0.880 |
Why?
| | Macrophages, Alveolar | 6 | 2024 | 391 | 0.880 |
Why?
| | Myocytes, Smooth Muscle | 7 | 2025 | 261 | 0.870 |
Why?
| | Bronchopulmonary Dysplasia | 3 | 2022 | 383 | 0.870 |
Why?
| | Superoxides | 2 | 2025 | 202 | 0.830 |
Why?
| | Cell Communication | 1 | 2025 | 315 | 0.820 |
Why?
| | Macrophages | 5 | 2025 | 1547 | 0.800 |
Why?
| | Inflammation | 10 | 2025 | 2837 | 0.770 |
Why?
| | Disease Models, Animal | 13 | 2025 | 4295 | 0.760 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 3 | 2017 | 28 | 0.690 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 234 | 0.650 |
Why?
| | Receptor, EphA2 | 2 | 2018 | 19 | 0.630 |
Why?
| | Neutrophils | 1 | 2025 | 1238 | 0.630 |
Why?
| | Pulmonary Fibrosis | 4 | 2017 | 402 | 0.620 |
Why?
| | Endothelium, Vascular | 4 | 2018 | 927 | 0.620 |
Why?
| | Alpha-Globulins | 2 | 2018 | 20 | 0.600 |
Why?
| | Mice, Knockout | 9 | 2025 | 3015 | 0.570 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2018 | 20 | 0.560 |
Why?
| | Protective Agents | 1 | 2018 | 41 | 0.560 |
Why?
| | Liposomes | 3 | 2017 | 223 | 0.540 |
Why?
| | Endothelial Cells | 4 | 2015 | 785 | 0.530 |
Why?
| | MicroRNAs | 2 | 2022 | 692 | 0.490 |
Why?
| | Staphylococcus aureus | 3 | 2025 | 450 | 0.490 |
Why?
| | Early Growth Response Protein 1 | 2 | 2011 | 27 | 0.460 |
Why?
| | Vasodilator Agents | 6 | 2017 | 331 | 0.440 |
Why?
| | Pulmonary Alveoli | 2 | 2021 | 405 | 0.430 |
Why?
| | Mice, Transgenic | 7 | 2025 | 2167 | 0.410 |
Why?
| | Signal Transduction | 7 | 2024 | 5079 | 0.410 |
Why?
| | Extracellular Space | 2 | 2011 | 119 | 0.410 |
Why?
| | Peptides | 2 | 2018 | 985 | 0.400 |
Why?
| | Oxidative Stress | 7 | 2025 | 1317 | 0.390 |
Why?
| | Metalloporphyrins | 1 | 2013 | 103 | 0.380 |
Why?
| | Mitochondria | 1 | 2019 | 948 | 0.380 |
Why?
| | Hemoglobins | 4 | 2017 | 353 | 0.380 |
Why?
| | Xanthine Oxidase | 1 | 2011 | 81 | 0.360 |
Why?
| | Inflammasomes | 1 | 2013 | 131 | 0.360 |
Why?
| | Animals, Newborn | 5 | 2022 | 844 | 0.360 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 171 | 0.350 |
Why?
| | Extracellular Matrix | 2 | 2025 | 528 | 0.340 |
Why?
| | Lipopolysaccharides | 4 | 2023 | 886 | 0.340 |
Why?
| | Cell Proliferation | 8 | 2022 | 2475 | 0.330 |
Why?
| | Male | 28 | 2025 | 67762 | 0.330 |
Why?
| | Up-Regulation | 2 | 2013 | 843 | 0.320 |
Why?
| | Muscle, Smooth, Vascular | 5 | 2025 | 446 | 0.310 |
Why?
| | Trachea | 1 | 2010 | 237 | 0.300 |
Why?
| | Carrier Proteins | 1 | 2013 | 771 | 0.290 |
Why?
| | Sildenafil Citrate | 2 | 2018 | 58 | 0.280 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 665 | 0.280 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2018 | 127 | 0.270 |
Why?
| | Energy Metabolism | 2 | 2024 | 922 | 0.270 |
Why?
| | Rats, Sprague-Dawley | 10 | 2018 | 2486 | 0.260 |
Why?
| | Electron Spin Resonance Spectroscopy | 2 | 2023 | 95 | 0.250 |
Why?
| | Kidney | 3 | 2024 | 1468 | 0.250 |
Why?
| | Cells, Cultured | 6 | 2021 | 4193 | 0.240 |
Why?
| | Acute Kidney Injury | 2 | 2024 | 815 | 0.230 |
Why?
| | Humans | 36 | 2024 | 137585 | 0.230 |
Why?
| | Platelet Factor 4 | 2 | 2025 | 35 | 0.230 |
Why?
| | Neutrophil Infiltration | 1 | 2025 | 107 | 0.230 |
Why?
| | Serotonin | 2 | 2024 | 323 | 0.230 |
Why?
| | Rats | 11 | 2018 | 5647 | 0.230 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 2024 | 26 | 0.220 |
Why?
| | Gene Expression Regulation | 5 | 2018 | 2607 | 0.220 |
Why?
| | Prolactin | 1 | 2024 | 96 | 0.220 |
Why?
| | Nanoparticles | 2 | 2021 | 481 | 0.220 |
Why?
| | Myofibroblasts | 3 | 2022 | 127 | 0.220 |
Why?
| | Hydroxylamine | 1 | 2023 | 7 | 0.210 |
Why?
| | Cellular Reprogramming | 1 | 2024 | 99 | 0.210 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2025 | 195 | 0.210 |
Why?
| | Interleukin-1beta | 2 | 2018 | 372 | 0.210 |
Why?
| | Influenza A virus | 1 | 2024 | 107 | 0.210 |
Why?
| | Fibroblast Growth Factors | 1 | 2024 | 172 | 0.210 |
Why?
| | Nitric Oxide | 4 | 2018 | 915 | 0.200 |
Why?
| | NF-kappa B | 3 | 2018 | 691 | 0.200 |
Why?
| | Familial Primary Pulmonary Hypertension | 4 | 2018 | 198 | 0.200 |
Why?
| | Coinfection | 1 | 2024 | 137 | 0.200 |
Why?
| | Liver | 2 | 2024 | 1943 | 0.200 |
Why?
| | Uncoupling Protein 2 | 1 | 2022 | 8 | 0.200 |
Why?
| | Hyaluronan Synthases | 1 | 2022 | 1 | 0.200 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2023 | 59 | 0.190 |
Why?
| | Glutathione | 1 | 2024 | 356 | 0.190 |
Why?
| | Wound Healing | 1 | 2025 | 331 | 0.190 |
Why?
| | Interleukin-10 | 1 | 2024 | 302 | 0.190 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2015 | 204 | 0.190 |
Why?
| | Adventitia | 2 | 2012 | 40 | 0.180 |
Why?
| | Dual-Specificity Phosphatases | 1 | 2021 | 11 | 0.180 |
Why?
| | Succinate Dehydrogenase | 1 | 2021 | 50 | 0.180 |
Why?
| | Chemokine CCL5 | 1 | 2020 | 43 | 0.170 |
Why?
| | Alveolar Epithelial Cells | 2 | 2023 | 114 | 0.170 |
Why?
| | Interferon-gamma | 1 | 2024 | 789 | 0.170 |
Why?
| | Cell Membrane Permeability | 2 | 2018 | 78 | 0.170 |
Why?
| | Placenta | 2 | 2024 | 750 | 0.170 |
Why?
| | Lung Diseases | 3 | 2017 | 767 | 0.160 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 152 | 0.160 |
Why?
| | Hemodynamics | 4 | 2018 | 1113 | 0.160 |
Why?
| | Staphylococcal Infections | 1 | 2024 | 400 | 0.160 |
Why?
| | Reperfusion Injury | 1 | 2022 | 279 | 0.150 |
Why?
| | Advisory Committees | 1 | 2020 | 219 | 0.150 |
Why?
| | Ephrin-A2 | 1 | 2018 | 4 | 0.150 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2017 | 652 | 0.150 |
Why?
| | Thrombocytopenia | 1 | 2020 | 200 | 0.150 |
Why?
| | Chronic Disease | 2 | 2017 | 1793 | 0.150 |
Why?
| | Heparitin Sulfate | 1 | 2018 | 50 | 0.150 |
Why?
| | Glycocalyx | 1 | 2018 | 27 | 0.150 |
Why?
| | Ketanserin | 1 | 2018 | 12 | 0.140 |
Why?
| | Drug Repositioning | 1 | 2018 | 35 | 0.140 |
Why?
| | Mucociliary Clearance | 1 | 2018 | 45 | 0.140 |
Why?
| | Receptors, CCR2 | 1 | 2018 | 40 | 0.140 |
Why?
| | Ventricular Pressure | 2 | 2015 | 48 | 0.140 |
Why?
| | Serotonin Antagonists | 1 | 2018 | 32 | 0.140 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2018 | 107 | 0.140 |
Why?
| | Glioma | 1 | 2022 | 395 | 0.140 |
Why?
| | Physical Exertion | 1 | 2018 | 215 | 0.140 |
Why?
| | Blood Pressure | 5 | 2022 | 1786 | 0.130 |
Why?
| | PPAR gamma | 1 | 2018 | 182 | 0.130 |
Why?
| | Toll-Like Receptor 9 | 1 | 2017 | 32 | 0.130 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2017 | 37 | 0.130 |
Why?
| | Caspase 1 | 2 | 2018 | 144 | 0.130 |
Why?
| | Arginine | 2 | 2014 | 271 | 0.130 |
Why?
| | rho-Associated Kinases | 2 | 2017 | 83 | 0.130 |
Why?
| | Heart Ventricles | 1 | 2021 | 788 | 0.120 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2022 | 605 | 0.120 |
Why?
| | Disease Progression | 3 | 2019 | 2757 | 0.120 |
Why?
| | Ventricular Function, Right | 2 | 2015 | 285 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 86 | 0.120 |
Why?
| | MAP Kinase Signaling System | 2 | 2021 | 320 | 0.120 |
Why?
| | Mice, Inbred BALB C | 1 | 2018 | 1272 | 0.120 |
Why?
| | Cholestasis | 1 | 2018 | 235 | 0.120 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2022 | 657 | 0.120 |
Why?
| | Administration, Inhalation | 4 | 2018 | 688 | 0.120 |
Why?
| | Haptoglobins | 1 | 2015 | 53 | 0.110 |
Why?
| | Anemia, Sickle Cell | 1 | 2018 | 270 | 0.110 |
Why?
| | Pericytes | 1 | 2014 | 34 | 0.110 |
Why?
| | Hyperoxia | 1 | 1995 | 90 | 0.110 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2014 | 137 | 0.110 |
Why?
| | Altitude | 1 | 2018 | 488 | 0.110 |
Why?
| | Fibroblasts | 4 | 2025 | 996 | 0.110 |
Why?
| | Female | 11 | 2025 | 73304 | 0.100 |
Why?
| | Vascular Diseases | 2 | 2015 | 243 | 0.100 |
Why?
| | Alprostadil | 1 | 2013 | 32 | 0.100 |
Why?
| | RNA, Small Interfering | 2 | 2015 | 622 | 0.100 |
Why?
| | I-kappa B Kinase | 1 | 2013 | 55 | 0.100 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 99 | 0.100 |
Why?
| | Apoptosis | 4 | 2022 | 2553 | 0.100 |
Why?
| | Lactic Acid | 3 | 2023 | 305 | 0.100 |
Why?
| | I-kappa B Proteins | 1 | 2013 | 81 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2015 | 545 | 0.100 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2015 | 238 | 0.100 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2013 | 93 | 0.100 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2015 | 201 | 0.090 |
Why?
| | Transcriptome | 1 | 2018 | 971 | 0.090 |
Why?
| | Protein Binding | 1 | 2018 | 2224 | 0.090 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2013 | 151 | 0.090 |
Why?
| | Altitude Sickness | 1 | 2013 | 153 | 0.090 |
Why?
| | Interleukin-18 | 1 | 2013 | 236 | 0.090 |
Why?
| | Catalase | 4 | 2015 | 130 | 0.090 |
Why?
| | Neoplasm Proteins | 1 | 2014 | 434 | 0.090 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 1 | 2011 | 51 | 0.090 |
Why?
| | Vasoconstrictor Agents | 2 | 2022 | 139 | 0.090 |
Why?
| | Blood Vessels | 1 | 2012 | 187 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1774 | 0.090 |
Why?
| | Transcriptional Activation | 1 | 2013 | 378 | 0.090 |
Why?
| | Drug Carriers | 3 | 2018 | 128 | 0.090 |
Why?
| | Phosphorylation | 1 | 2015 | 1759 | 0.090 |
Why?
| | Rats, Inbred WKY | 1 | 2010 | 36 | 0.090 |
Why?
| | Drug Administration Routes | 1 | 2010 | 38 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 2129 | 0.090 |
Why?
| | Blood Circulation | 1 | 2010 | 41 | 0.090 |
Why?
| | Nitrosation | 1 | 2010 | 8 | 0.090 |
Why?
| | Accreditation | 1 | 2011 | 83 | 0.080 |
Why?
| | Stress, Physiological | 2 | 2012 | 443 | 0.080 |
Why?
| | Airway Remodeling | 1 | 2011 | 64 | 0.080 |
Why?
| | Microvessels | 1 | 2011 | 88 | 0.080 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3284 | 0.080 |
Why?
| | Inflammation Mediators | 1 | 2013 | 513 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 2 | 2015 | 2426 | 0.080 |
Why?
| | Tyrosine | 1 | 2010 | 222 | 0.080 |
Why?
| | Models, Biological | 1 | 2017 | 1783 | 0.080 |
Why?
| | Phenotype | 2 | 2015 | 3196 | 0.080 |
Why?
| | Vasoconstriction | 1 | 2010 | 202 | 0.080 |
Why?
| | Workload | 1 | 2011 | 167 | 0.080 |
Why?
| | Cattle | 1 | 2011 | 984 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2018 | 1291 | 0.080 |
Why?
| | Fetus | 1 | 2013 | 806 | 0.070 |
Why?
| | Gene Expression | 1 | 2013 | 1502 | 0.070 |
Why?
| | Transforming Growth Factor beta | 1 | 2010 | 480 | 0.070 |
Why?
| | Porosity | 2 | 2018 | 102 | 0.070 |
Why?
| | Time Factors | 1 | 2018 | 6828 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2022 | 278 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 916 | 0.060 |
Why?
| | Sheep | 2 | 2022 | 856 | 0.060 |
Why?
| | Education, Medical, Graduate | 1 | 2011 | 486 | 0.060 |
Why?
| | Antioxidants | 3 | 2014 | 584 | 0.060 |
Why?
| | Critical Care | 1 | 2011 | 601 | 0.060 |
Why?
| | Polyglycolic Acid | 2 | 2017 | 43 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2024 | 3556 | 0.060 |
Why?
| | Sulfonamides | 2 | 2022 | 513 | 0.060 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2024 | 27 | 0.060 |
Why?
| | Schistosoma | 1 | 2024 | 28 | 0.060 |
Why?
| | Complement C5a | 1 | 2024 | 71 | 0.060 |
Why?
| | Lipid Peroxidation | 2 | 2017 | 153 | 0.060 |
Why?
| | Complement C3a | 1 | 2024 | 42 | 0.060 |
Why?
| | Schistosomiasis | 1 | 2024 | 47 | 0.050 |
Why?
| | Epithelial Cells | 1 | 2010 | 1096 | 0.050 |
Why?
| | Maternal Behavior | 1 | 2024 | 78 | 0.050 |
Why?
| | Pituitary Gland | 1 | 2024 | 148 | 0.050 |
Why?
| | Cell Line | 3 | 2015 | 2847 | 0.050 |
Why?
| | Orthomyxoviridae Infections | 1 | 2024 | 67 | 0.050 |
Why?
| | Vascular Resistance | 2 | 2015 | 375 | 0.050 |
Why?
| | Nitrogen Oxides | 1 | 2023 | 55 | 0.050 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2015 | 139 | 0.050 |
Why?
| | Phosphofructokinase-2 | 1 | 2022 | 15 | 0.050 |
Why?
| | Gene Deletion | 1 | 2024 | 391 | 0.050 |
Why?
| | Breath Tests | 1 | 2023 | 87 | 0.050 |
Why?
| | Spectrum Analysis | 1 | 2023 | 91 | 0.050 |
Why?
| | Pediatrics | 1 | 2011 | 1101 | 0.050 |
Why?
| | Creatinine | 1 | 2024 | 499 | 0.050 |
Why?
| | Lasers | 1 | 2023 | 130 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2011 | 1996 | 0.050 |
Why?
| | Tryptophan Hydroxylase | 1 | 2022 | 53 | 0.050 |
Why?
| | Glycolysis | 1 | 2024 | 321 | 0.050 |
Why?
| | Radiation, Ionizing | 1 | 2022 | 80 | 0.050 |
Why?
| | Hydrogen Peroxide | 2 | 2012 | 328 | 0.050 |
Why?
| | Biomarkers | 2 | 2024 | 4149 | 0.050 |
Why?
| | Cerium | 1 | 2021 | 14 | 0.050 |
Why?
| | 3' Untranslated Regions | 1 | 2022 | 145 | 0.050 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2022 | 126 | 0.050 |
Why?
| | Complement System Proteins | 1 | 2024 | 327 | 0.040 |
Why?
| | Complement Activation | 1 | 2024 | 415 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 233 | 0.040 |
Why?
| | Ischemia | 1 | 2024 | 409 | 0.040 |
Why?
| | Angiotensin II | 1 | 2021 | 99 | 0.040 |
Why?
| | Metabolome | 1 | 2024 | 350 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2022 | 247 | 0.040 |
Why?
| | Pregnancy | 2 | 2024 | 6763 | 0.040 |
Why?
| | Internship and Residency | 1 | 2011 | 1147 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 227 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2023 | 496 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2024 | 6079 | 0.040 |
Why?
| | Mutation | 1 | 2011 | 3958 | 0.040 |
Why?
| | Time-to-Treatment | 1 | 2021 | 205 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 552 | 0.040 |
Why?
| | Critical Pathways | 1 | 2020 | 96 | 0.040 |
Why?
| | Syndecans | 1 | 2018 | 5 | 0.040 |
Why?
| | Metabolomics | 1 | 2024 | 678 | 0.040 |
Why?
| | Heart Function Tests | 1 | 2018 | 59 | 0.040 |
Why?
| | Caspases, Initiator | 1 | 2018 | 17 | 0.040 |
Why?
| | Amino Acid Oxidoreductases | 2 | 1995 | 19 | 0.040 |
Why?
| | Liver X Receptors | 1 | 2018 | 31 | 0.040 |
Why?
| | Information Dissemination | 1 | 2020 | 218 | 0.040 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2018 | 38 | 0.040 |
Why?
| | Drug Liberation | 1 | 2018 | 35 | 0.040 |
Why?
| | Endothelins | 1 | 2018 | 65 | 0.040 |
Why?
| | Needs Assessment | 1 | 2020 | 376 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2023 | 1946 | 0.040 |
Why?
| | Influenza, Human | 1 | 2024 | 622 | 0.040 |
Why?
| | Capillary Permeability | 1 | 2018 | 145 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2020 | 283 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2022 | 746 | 0.040 |
Why?
| | Drug Compounding | 1 | 2018 | 101 | 0.030 |
Why?
| | Genotype | 2 | 2014 | 1916 | 0.030 |
Why?
| | Nitric Oxide Synthase | 2 | 1995 | 240 | 0.030 |
Why?
| | Stem Cells | 2 | 2012 | 594 | 0.030 |
Why?
| | Monocrotaline | 1 | 2017 | 28 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2018 | 216 | 0.030 |
Why?
| | Anemia, Hemolytic | 1 | 2017 | 20 | 0.030 |
Why?
| | Polyethyleneimine | 1 | 2017 | 18 | 0.030 |
Why?
| | Caspases | 1 | 2018 | 247 | 0.030 |
Why?
| | Lipoproteins | 1 | 2018 | 168 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1710 | 0.030 |
Why?
| | Parenteral Nutrition | 1 | 2018 | 107 | 0.030 |
Why?
| | Hepatocytes | 1 | 2018 | 220 | 0.030 |
Why?
| | Glucose | 1 | 2022 | 1020 | 0.030 |
Why?
| | Hemolysis | 1 | 2018 | 206 | 0.030 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2017 | 105 | 0.030 |
Why?
| | Acclimatization | 1 | 2018 | 177 | 0.030 |
Why?
| | Histones | 1 | 2022 | 636 | 0.030 |
Why?
| | Microspheres | 1 | 2017 | 137 | 0.030 |
Why?
| | Rabbits | 2 | 1995 | 794 | 0.030 |
Why?
| | Models, Animal | 1 | 2018 | 384 | 0.030 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 220 | 0.030 |
Why?
| | Critical Illness | 1 | 2022 | 811 | 0.030 |
Why?
| | Program Evaluation | 1 | 2020 | 898 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2017 | 126 | 0.030 |
Why?
| | Sex Factors | 1 | 2022 | 2071 | 0.030 |
Why?
| | Surface Properties | 1 | 2017 | 413 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1079 | 0.030 |
Why?
| | Cytokines | 1 | 2023 | 2085 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1066 | 0.030 |
Why?
| | Particle Size | 1 | 2017 | 394 | 0.030 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 1995 | 48 | 0.030 |
Why?
| | Free Radicals | 1 | 1995 | 110 | 0.030 |
Why?
| | Pulmonary Edema | 1 | 1995 | 108 | 0.030 |
Why?
| | Sepharose | 1 | 2014 | 34 | 0.030 |
Why?
| | Administration, Oral | 1 | 2017 | 816 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2022 | 3412 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 239 | 0.030 |
Why?
| | Platelet Activating Factor | 1 | 1994 | 76 | 0.030 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2014 | 165 | 0.030 |
Why?
| | Glycine | 1 | 2014 | 176 | 0.030 |
Why?
| | Permeability | 1 | 2013 | 161 | 0.030 |
Why?
| | Endothelin-1 | 1 | 2015 | 182 | 0.030 |
Why?
| | 1,2-Dipalmitoylphosphatidylcholine | 1 | 2013 | 10 | 0.030 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2013 | 54 | 0.030 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2013 | 56 | 0.030 |
Why?
| | Infant, Premature | 1 | 2017 | 574 | 0.030 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2013 | 122 | 0.020 |
Why?
| | Vasa Vasorum | 1 | 2012 | 25 | 0.020 |
Why?
| | von Willebrand Factor | 1 | 2013 | 80 | 0.020 |
Why?
| | Heparin | 1 | 2014 | 261 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2013 | 132 | 0.020 |
Why?
| | Cyclic N-Oxides | 1 | 2012 | 29 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2017 | 778 | 0.020 |
Why?
| | Drug Stability | 1 | 2013 | 167 | 0.020 |
Why?
| | Infusion Pumps | 1 | 2012 | 32 | 0.020 |
Why?
| | Iron | 1 | 2015 | 313 | 0.020 |
Why?
| | Spin Labels | 1 | 2012 | 48 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 2013 | 148 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2013 | 181 | 0.020 |
Why?
| | Quality Improvement | 1 | 2020 | 1178 | 0.020 |
Why?
| | Cardiac Output | 1 | 2012 | 165 | 0.020 |
Why?
| | Aerosols | 1 | 2013 | 176 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1639 | 0.020 |
Why?
| | Cohort Studies | 1 | 2022 | 5742 | 0.020 |
Why?
| | Receptor, TIE-2 | 1 | 2011 | 12 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 243 | 0.020 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 273 | 0.020 |
Why?
| | Cerebellum | 1 | 2013 | 224 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2014 | 812 | 0.020 |
Why?
| | Cholesterol | 1 | 2013 | 410 | 0.020 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2011 | 135 | 0.020 |
Why?
| | Vasculitis | 1 | 2011 | 66 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4565 | 0.020 |
Why?
| | Oxygen | 1 | 1995 | 931 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7604 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 1226 | 0.020 |
Why?
| | Cell Survival | 1 | 2013 | 1120 | 0.020 |
Why?
| | Vasodilation | 1 | 2013 | 499 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1062 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2013 | 2833 | 0.020 |
Why?
| | Thrombosis | 1 | 2011 | 371 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1250 | 0.020 |
Why?
| | Genes | 1 | 1986 | 230 | 0.020 |
Why?
| | Infant | 1 | 2017 | 9465 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2018 | 10811 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2011 | 1991 | 0.010 |
Why?
| | Aged | 1 | 2022 | 23961 | 0.010 |
Why?
| | Child | 1 | 2022 | 21935 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1986 | 1457 | 0.010 |
Why?
| | Risk Factors | 1 | 2014 | 10388 | 0.010 |
Why?
| | Ditiocarb | 1 | 1994 | 3 | 0.010 |
Why?
| | 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 1994 | 10 | 0.010 |
Why?
| | Thromboxane A2 | 1 | 1994 | 11 | 0.010 |
Why?
| | United States | 1 | 2011 | 14841 | 0.010 |
Why?
| | Epoprostenol | 1 | 1994 | 136 | 0.010 |
Why?
| | Perfusion | 1 | 1994 | 213 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 1994 | 1092 | 0.010 |
Why?
| | Rats, Inbred Strains | 1 | 1986 | 362 | 0.000 |
Why?
| | Molecular Weight | 1 | 1986 | 335 | 0.000 |
Why?
| | Tissue Distribution | 1 | 1986 | 332 | 0.000 |
Why?
| | Aging | 1 | 1986 | 1864 | 0.000 |
Why?
|
|
Nozik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|